Dersimelagon (MT-7117)

Name: Dersimelagon (MT-7117) in Erythropoietic protoporphyria or X-linked protoporphyria: Administration
Published: 2026-09-21T21:42:40-04:00

Erythropoietic protoporphyria or X-linked protoporphyria

Manufacturer: LEO Pharma
Regulatory submission: NDA submitted June 2026
Launch: Potential launch in 2027
Last updated: September 21, 2026

Section

Product information and disease description Product description Product information Dosing and administration

Administration

2 evidence topics · 3 sources

Oral once-daily administration

“Dersimelagon is an investigational, once-daily oral small-molecule MC1R agonist being developed for EPP and XLP.” (opens the source at this quote in a new tab)

“Oral tablet of MT-7117 Low Dose once a day.” (opens the source at this quote in a new tab)

Administration with respect to food

“No effect was observed on overall exposure (area under the plasma concentration versus time curve [AUC]) following consumption of a high-fat meal, and Cmax was higher (22%, 90% confidence interval [CI] 1.05-1.42) in a fed state compared with fasted conditions.” (opens the source at this quote in a new tab)